HPGDS inhibitor 1


CAS No. : 1033836-12-2

HPGDS inhibitor 1,1033836-12-2
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000204
Synonyms:6-(3-fluorophenyl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
Molecular Formula:C19H19F4N3O
Molecular Weight:381.4
Target:PGDS
IC50:0.7 nM [1]
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:Solid powder
Purity: > 98%
Cat No:I000204
Cas No:1033836-12-2
Product-Name:HPGDS inhibitor 1
InChI:InChI=1S/C19H19F4N3O/c20-15-3-1-2-13(10-15)17-5-4-14(11-24-17)18(27)25-16-6-8-26(9-7-16)12-19(21,22)23/h1-5,10-11,16H,6-9,12H2,(H,25,27)
InChIKey:LPUCBGGXXIUBAZ-UHFFFAOYSA-N
SMILES:O=C(C1=CC=C(C2=CC=CC(F)=C2)N=C1)NC3CCN(CC(F)(F)F)CC3

HPGDS inhibitor 1 is a novel and selective Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50 Value of 0.7 nM.
IC50 Value: 0.7 nM [1]
Target: HPGDS
HPGDS inhibitor 1 was elected for further profiling based on its enzyme and cell potency. The compound illustrated equal potency against purified HPGDS from human , rat, dog, and sheep (IC50, 0.5-2.3 nM). HPGDS inhibitor 1 was profiled in a panel of cellular assays to screen for activity against several relevant human enzyme targets. Those assay indicated that HPGDS inhibitor 1 does not inhibit human L- PGDS, m-PGDS, COX-1, COX-2 or 5 LOX (IC50 values > 10000 nM).
HPGDS inhibitor 1 had a solubility of 1.5 ug/ml (3.9 uM) at pH 6.5. The compound had excellent PK characteristics when dosed in rats at 1 mpk with 76% bioavailavility.
Rats dosed orally with 1 and 10 mpk HPGDS inhibitor 1 were sacrificed at various times, and plasma concentrations of HPGDS inhibitor 1 and spleen PGD2 concentrations were measured. Oral administration of HPGDS inhibitor 1 blocked PGD2 production in the rat spleen; inhibition of PGD2 was inversely correlated with the plasma concentration of HPGDS inhibitor 1 in a time and dose-dependent manner. Spleen PGD2 levels fall as HPGDS inhibitor 1 plasma levels increase over time; PGD2 levels return to baseline levels as HPGDS inhibitor 1 plasma levels decline.


[1]. Chris P. Carron, et al. Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS). ACS Med. Chem. Lett., 2010, 1 (2), pp 59-63 Abstract Hematopoietic prostaglandin D synthase (HPGDS) is primarly expressed in mast cells, antigen-presenting cells, and Th-2 cells. HPGDS converts PGH(2) into PGD(2), a mediator thought to play a pivotal role in airway allergy and inflammatory processes. In this letter, we report the discovery of an orally potent and selective inhibitor of HPGDS that reduces the antigen-induced response in allergic sheep.

Recommended Products
  • CAS No. :1246892-67-0
    Product Name:

    4H-Oxazolo[4,5-c]azepine, 5,6,7,8-tetrahydro-2-(2-pyridinyl)-

    Cat No: M031741 View details
  • CAS No. :1272756-19-0
    Product Name:

    Methyl N-Boc-2-broMo-5-sulfaMoylbenzoate

    Cat No: M031742 View details
  • CAS No. :1256791-82-8
    Product Name:

    4-Pyridinecarboxylic acid, 3-chloro-5-Methyl-, Methyl ester

    Cat No: M031743 View details
  • CAS No. :1248826-72-3
    Product Name:

    2,3-Pyrrolidinedione, 4,4-diMethyl-

    Cat No: M031744 View details